AOLS:OTC-Aeolus Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.02M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Aeolus Pharmaceuticals Inc (AOLS) Stock Analysis:
Based on the Aeolus Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Aeolus Pharmaceuticals Inc is not available over the next 12 months. Aeolus Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aeolus Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Aeolus Pharmaceuticals Inc’s stock price was USD 0.00. Aeolus Pharmaceuticals Inc’s stock price has changed by 0% over the past week, -100.00% over the past month and -100.00% over the last year.

No recent analyst target price found for Aeolus Pharmaceuticals Inc
No recent average analyst rating found for Aeolus Pharmaceuticals Inc

About

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as me ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.45 (+1.36%)

USD72.20B 22.76 13.89
MKGAF MERCK Kommanditgesellschaft au..

+4.00 (+2.41%)

USD72.00B 22.44 13.89
TKPHF Takeda Pharmaceutical Company ..

+0.31 (+1.10%)

USD44.09B 13.07 0.06
SGIOF Shionogi & Co. Ltd

+0.05 (+0.09%)

USD16.01B 21.15 0.11
SGIOY Shionogi & Co. Ltd

+0.01 (+0.11%)

USD16.01B 21.17 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

-0.15 (-3.33%)

USD15.75B 17.30 2.67
ESALF Eisai Co. Ltd

N/A

USD12.67B 27.89 0.10
ESALY Eisai Co. Ltd

-0.44 (-1.01%)

USD12.09B 27.39 0.10
GNHAF Vifor Pharma AG

N/A

USD11.36B 77.87 17.10
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing AOLS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 25.61% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.61% 59% F 61% D-
Risk Return Profile  
Volatility (Standard Deviation) 196.01% 31% F 23% F
Risk Adjusted Return 13.07% 51% F 36% F
Market Capitalization 0.02M 6% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.81 63% D 71% C-
Price / Cash Flow Ratio -0.01 34% F 57% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -186.43% 23% F 8% F
Return on Invested Capital -195.58% 10% F 5% F
Return on Assets -90.30% 14% F 11% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.08 21% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.